Glucagon-like peptide-1 (GLP-1) agonists are rapidly gaining popularity as an effective way to lose weight, so much so that bariatric surgery is at risk of becoming a thing of the past.
A study spearheaded by Thomas Tsai, assistant professor at the Harvard T.H. Chan School of Public Health, revealed a 25.6% decrease in the number of bariatric surgery patients in the latter half of 2023 compared to the latter half of 2022. Meanwhile, the number of GLP-1 users spiked to 132.6% in the same timeframe. (1)
Continue reading Rise Of GLP-1 Injections In New Jersey, Fall Of Weight Loss Surgeons